Abstract
Modified Vaccinia Virus Ankara (MVA) is employed widely as an experimental vaccine vector for its lack of replication in mammalian cells and high expression level of foreign/heterologous genes. Recombinant MVAs (rMVAs) are used as platforms for protein production as well as vectors to generate vaccines against a high number of infectious diseases and other pathologies. The portrait of the virus combines desirable elements such as high-level biological safety, the ability to activate appropriate innate immune mediators upon vaccination, and the capacity to deliver substantial amounts of heterologous antigens. Recombinant MVAs encoding proteins of bluetongue virus (BTV), an Orbivirus that infects domestic and wild ruminants transmitted by biting midges of the Culicoides species, are excellent vaccine candidates against this virus. In this chapter we describe the methods for the generation of rMVAs encoding VP2, NS1, and VP7 proteins of bluetongue virus as a model example for orbiviruses. The protocols included cover the cloning of VP2, NS1, and VP7 BTV-4 genes in a transfer plasmid, the construction of recombinant MVAs, the titration of virus working stocks and the protein expression analysis by immunofluorescence and radiolabeling of rMVA infected cells as well as virus purification.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sutter G, Staib C (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3:263–271
Melamed S, Wyatt LS, Kastenmayer RJ et al (2013) Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants. Vaccine 31:4569–4577
Calvo-Pinilla E, Castillo-Olivares J, Jabbar T et al (2014) Recombinant vaccines against bluetongue virus. Virus Res 182:78–86
Esteban M (2009) Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 5:867–871
Garcia-Arriaza J, Esteban M (2014) Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother 10:2235–2245
Ramirez JC, Gherardi MM, Esteban M (2000) Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74:923–933
Le Bon A, Durand V, Kamphuis E et al (2006) Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176:4682–4689
Tough DF (2004) Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 45:257–264
Chakrabarti S, Brechling K, Moss B (1985) Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5:3403–3409
Calvo-Pinilla E, de la Poza F, Gubbins S et al (2014) Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation. Virus Res 180:23–30
Ortego J, de la Poza F, Marin-Lopez A (2014) Interferon alpha/beta receptor knockout mice as a model to study bluetongue virus infection. Virus Res 182:35–42
de la Poza F, Calvo-Pinilla E, Lopez-Gil E et al (2013) Ns1 is a key protein in the vaccine composition to protect Ifnar(−/−) mice against infection with multiple serotypes of African horse sickness virus. PLoS One 8:e70197
Jabbar TK, Calvo-Pinilla E, Mateos F et al (2013) Protection of IFNAR (−/−) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS One 8:e60574
Calvo-Pinilla E, Navasa N, Anguita J et al (2012) Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 7:e34735
Calvo-Pinilla E, Rodriguez-Calvo T, Sevilla N et al (2009) Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(−/−) mice against lethal bluetongue infection. Vaccine 28:437–445
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Marín-López, A., Ortego, J. (2016). Generation of Recombinant Modified Vaccinia Virus Ankara Encoding VP2, NS1, and VP7 Proteins of Bluetongue Virus. In: Brun, A. (eds) Vaccine Technologies for Veterinary Viral Diseases. Methods in Molecular Biology, vol 1349. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3008-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3008-1_9
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3007-4
Online ISBN: 978-1-4939-3008-1
eBook Packages: Springer Protocols